LFG
TBPH icon

Larson Financial Group’s Theravance Biopharma TBPH Stock Holding History

Larson Financial Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.58K Buy
328
+49
+18% +$811 ﹤0.01% 2721
2026
Q1 		$4.53K Buy
279
+109
+64% +$1.93K ﹤0.01% 2652
2025
Q4 		$3.18K Hold
170
– – ﹤0.01% 2643
2025
Q3 		$2.48K Hold
170
– – ﹤0.01% 2615
2025
Q2 		$1.88K Buy
170
+116
+215% +$1.13K ﹤0.01% 2428
2025
Q1 		$482 Buy
+54
New +$503 ﹤0.01% 2586

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Larson Financial Group's TBPH Position: Q2 2026 in Review

Larson Financial Group increased its Theravance Biopharma (TBPH) stake by 18% in Q2 2026, buying an estimated $811 and bringing the position to 328 shares worth $5.58K. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Larson Financial Group first reported a position in TBPH in Q1 2025 and has held it in 6 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Larson Financial Group held 328 shares of Theravance Biopharma worth $5.58K as of Q2 2026.
  • Larson Financial Group bought 49 Theravance Biopharma shares in Q2 2026, an estimated $811.
  • Theravance Biopharma made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2721 holding.
  • Larson Financial Group first reported a position in Theravance Biopharma in Q1 2025 and has held it in 6 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.